The Impact of Inflammatory Burden Index on the Prognosis in Acute Decompensated Heart Failure: Evidence from a Cohort Study in Jiangxi, China

Kun Jiang^1,2Guoan Jian^1,2Zihao Lu^1,2Shiming He^1,2Xinfang Huang¹Lin Xie¹Shuhua Zhang¹Qun Wang¹Hengcheng Lu¹Zhiyu Xiong¹Zhiting Wu¹Guotai Sheng¹Yang Zou^1*Aimin Xie^1*Hengli Lai^1*Wei Wang^1*

• ¹Jiangxi Provincial People's Hospital, Nanchang, China
• ²Nanchang University, Nanchang, Jiangxi Province, China

Objective: Acute decompensated heart failure (ADHF) is the most common and severe type of HF. The aim of this study is to evaluate the impact and predictive value of a novel inflammatory marker, the inflammatory burden index (IBI), on the 30-day mortality and adverse prognosis in patients with ADHF. Methods: This retrospective cohort study included 1,241 ADHF patients from Jiangxi Provincial People's Hospital between 2018 and 2024. The IBI was calculated as C-reactive protein × (neutrophil count / lymphocyte count). In the event analysis, the study outcome was defined as the 30-day mortality rate after hospital admission in ADHF patients. Multivariable Cox regression and receiver operating characteristic curve analysis were used to assess the impact and predictive value of the IBI on 30-day mortality. Additionally, subgroup analyses were performed to determine the risk dependency of the IBI within specific populations. Results: During the 30-day observation period, a total of 108 death events (8.70%) were recorded. When the study population was stratified into tertiles based on the IBI, the 30-day mortality rates were 1.93%, 4.60%, and 19.57%, respectively. Multivariable Cox regression analysis revealed a significant positive association between the IBI and 30-day mortality in ADHF patients. Compared to ADHF patients with a low IBI (T1), those with a high IBI (T3) showed a 368% higher risk of 30-day mortality. Subgroup analysis revealed a significant interaction between the IBI and 30-day mortality in ADHF patients across sex 2 / 26 subgroups (P-interaction < 0.05). In particular, compared to male patients, female ADHF patients exhibited a significantly higher risk of IBI-related in-hospital all-cause mortality (HR: 1.52 vs. 1.33). Receiver operating characteristic analysis further demonstrated that the novel inflammatory marker IBI had the highest AUC value (0.80) compared to conventional inflammatory markers, including C-reactive protein, white blood cell count, neutrophil count, lymphocyte count, and monocyte count. Conclusion: The cohort study conducted in Jiangxi, China, revealed that the novel inflammatory marker IBI is significantly positively associated with 30-day mortality in ADHF patients and demonstrated strong predictive value. Incorporating IBI into the clinical management of ADHF patients may hold significant potential for preventing further disease deterioration.